glp 1 agonists with cardiovascular benefit Frontiers Cardiovascular outcomes trials for GLP-1

These vouchers followed agreements from Novo Nordisk and Lilly to cut prices on the drugs for Medicaid and Medicare patients

For example, in the lungs, GLP-1s may reduce the inflammatory response, improve oxidative stress, regulate protease/anti-protease imbalance, improve airway mucus homeostasis, and reduce airway remodeling to provide benefit in patients with COPD

Dosing starts low and escalates gradually

CurrOpinEndocrinol Diabetes Obes

GLP-1 encourages the pancreas to create insulin, blocks glucagon secretion and glucose production, slows digestion, and affects parts of the brain that are involved in hunger and fullness

This therapy mimics natural hormones that regulate appetite and metabolism, leading to sustainable results